Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ALYA Cost cutting system via software as well as security -- Ignore unavailable to you. Want to Upgrade?

To: John S. Baker who wrote (1479)	7/27/1998 1:35:00 PM
From: TLWatson59	Read Replies (2) \| Respond to of 2534

Mr. baker: that's the crux of the matter. The good dr. quackenbush and his companion ali baba would have you believe this is strictly MM manipulation in cahoots with the infamous amorphorous "short seller" cabel. A far better educated guess would be the back door, albeit legal, share selling abroad. Don't you find it odd that since the "audited" filing covering the period ending Sept. '97 and the unaudited filing ending March 31, 1998 show little if any concrete information as to where the funds from these stock sales went. I implore you to read the 3/31/98 balance sheet. It is available from the company. Then ask yourself a simple question. If Dr. Q is accurate in his assertion that almost $3 million flowed into the company and the bulk of it was spent on R & D, even if the money was expensed rather then capitalized, what is there to show in the cash flow statement to account for it. Even allowing for some degree of truth about R & D expenditures, whose $ value is disclosed nowhere in the financial statement, wouldn't any normal analysis of this company's financial picture raise more questions than it answers? Instead, we are asked to rely on verbal statements attributed to company spokesmen. Why? Both audited and unaudited statements exist and neither one of them answers the question any shape or manner other than the following which I quote from both statements: " Capital assets are stated at net book value and are amortized over their useful lives at the following rates." The statement then lists 4 items and their depreciation schedule. As to Research and development costs the following statement: "Research and development costs are expensed as they are incurred." Nothing listed. I leave to your judgement, if this sound like normal basic business practice for a publicly owned company. As to your question about "trading activity" what other conclusion can be drawn from a stock whose price has risen from 21 cents a share to $1.69 on trading volume exceeding even its total outstanding number shares and then returns to a price of 5/8 of a dollar other than an outflow of market capital. All of this in the face of one seemingly positive corporate announcement after another. Perhaps only my sense of proportion is unbalanced, but I think not.